Gain insights from our experts...
Optimizing lipid nanoparticles (LNPs) processing for siRNA delivery by microfluidics system
The success of mRNA vaccines during the COVID-19 pandemic has accelerated the advancement of nucleic acid delivery technologies. In addition to mRNA, interfering RNA offers potential to treat diseases beyond the reach of small molecules. However, therapeutic success hinges on efficient and targeted delivery systems. Lipid nanoparticles (LNPs), especially those produced via microfluidics, have emerged as a leading platform for RNA delivery. delivery. for RNA.
Join Dr. Qiaobin Hu as he explores LNP formulation for siRNA delivery using a microfluidic flow-focusing system.
Optimising lipid nanoparticles (LNPs) processing for siRNA delivery by microfluidics system
866.3 KB
Explore our poster presentation with Qiaobin Hu
Explore additional content
Explore recent blogs:
Croda’s Avanti Research™ expands advanced lipid technologies through collaboration with NovoArc
Avanti Polar Lipids, LLC, a wholly owned subsidiary of Croda International Plc, and NovoArc GmbH (NovoArc) are pleased to announce a strategic collaboration to expand global access to advanced lipid...
Partnership to protect biodiversity
Discover how Sustainably Sourced Squalene relates to the advice from the IPBES, the Intergovernmental Science-Policy Platform on Biodiversity and Ecosystem Services (IPBES).
Replacing Triton™ X‑100 Without Compromise: Meet Virodex™
If you were at BioProcess International Europe this year, you may have caught a glimpse of us talking about detergent alternatives for viral inactivation. If you weren’t, or if you’ve since heard the...